BALTIMORE, Maryland, November 13, 2015 /PRNewswire/ --
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued an initiation of coverage of report on BioSig Technologies, Inc. (OTC - BSGM), a medical device company. The report carries a rating and a price target. To view the new sponsored research report, along with disclosures and disclaimers, or to download them in their entirety, please visit http://www.GoldmanResearch.com.
Innovative medical device company BioSig Technologies is set to transform its segment of the $3 billion electrophysiology (EP) marketplace. The Company's flagship platform fulfills an unmet need by enhancing the efficacy, diagnostic value, and reduced timeframe of EP studies used in cardiac ablation procedures and could even increase the use of ablation procedures.
In the report, analyst Rob Goldman discusses the Company's enviable positioning, unmatched leadership team, and a series of key milestones ahead which should serve as trigger for the Company's higher standing and valuation among its peers.
"A series of milestones in the coming quarters should foster considerable recognition of BioSig's prospects. These include the results of recent and future preclinical studies, the filing for FDA 510(k) clearance to market its platform, and an up-list to NASDAQ. Meanwhile, the Company's positioning substantially increases the likelihood of major success ahead. For example, the Company has collaborated with the leading cardiac centers in the country such as the Mayo Clinic, UCLA Cardia Arrhythmia Center, and Mount Sinai Medical. Moreover, BioSig's leadership team reads like a Who's Who of C-level executives with a history of clinical, corporate, financial, and operational successes.
Separately, since large medical device firms have a demonstrated appetite for buying emerging EP company leaders, BioSig could emerge as a future target."
About Goldman Small Cap Research: Founded in 2009, by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored research report on BioSig Technologies, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from BioSig Technologies, Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com. Goldman Small Cap Research has been compensated by a third party in the amount of $3500 for investment research services that includes the publication of a research report.
About BioSig Technologies, Inc.: BioSig Technologies (OTC - BSGM) is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System. More information on BSGM can be found at http://www.BioSigTech.com.
Goldman Small Cap Research
Rob Goldman, Analyst
SOURCE Goldman Small Cap Research